Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047133 · ClinicalTrials.gov registry record · Phase 2
Effect of Early Administration of TXA in Adult Hip Fractures
A Phase 2 study of Postoperative Blood Loss, sponsored by Ascension Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT05047133 is a Phase 2 study of Postoperative Blood Loss that is actively recruiting participants, run by Ascension Health. The registered enrollment target is 170 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05047133, a Phase 2 study of Postoperative Blood Loss, is actively recruiting participants, sponsored by Ascension Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Michigan
- Ascension Genesys Hospital - Grand Blanc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047133
The ClinicalTrials.gov registry entry for NCT05047133 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascension Health, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postoperative Blood Loss appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT05047133 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05047133 about?
NCT05047133 is a clinical study titled "Effect of Early Administration of TXA in Adult Hip Fractures". This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperativ...
What is the current status of trial NCT05047133?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2021-09-01. Estimated completion is 2022-07-01.
What conditions does trial NCT05047133 study?
This clinical trial studies the following conditions: Postoperative Blood Loss.
What interventions are being tested in trial NCT05047133?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT05047133?
This trial is sponsored by Ascension Health, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05047133 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Blood Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.